Migration patterns of nonspecifically activated versus nonactivated nonhuman primate T lymphocytes: Preferential homing of activated autologous CD8+ T cells in the rectal mucosa

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 334-344

  Allers, Kristina ^a   Kunkel, Désirée ^a,c   Moos, Verena ^a   Eisenblätter, Martin ^a   Stahl Hennig, Christiane ^b   Kaup, Franz Josef ^b   Ignatius, Ralf ^a   Schneider, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

^c INSTITUT PASTEUR   (France)

Author keywords

Adoptive cell transfer; Autologous T cells; Migration; Nonhuman primate model; Persistence

Indexed keywords

ANTIBODY; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD28 ANTIBODY; CD3 ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; DUODENUM BIOPSY; FLOW CYTOMETRY; IMMUNOTHERAPY; IN VITRO STUDY; LABELING INDEX; LYMPH NODE BIOPSY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; LYMPHOCYTE TRANSFER; MACACA; NONHUMAN; ORAL BIOPSY; PRIMATE; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; FLUORESCEINS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACACA MULATTA; RECTUM; SUCCINIMIDES; TRANSPLANTATION, AUTOLOGOUS;

EID: 42649088422     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181635e7f     Document Type: Article

References (51)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
2. Rooney CM, Roskrow MA, Smith CA, et al. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998;23:89-93.
3. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol. 1986;39:585-589.
4. Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182:318-324.
5. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
6. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
7. Guidoboni M, Gafa R, Viel A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol. 2001;159:297-304.
8. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168-16173.
9. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883-1886.
10. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292-6300.
11. Osanto S, Schiphorst PP, Weijl NI, et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther. 2000;11:739-750.
12. Rodolfo M, Zilocchi C, Cappetti B, et al. Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine. Gene Ther. 1999;6:865-872.
13. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130.
14. Zhou J, Dudley ME, Rosenberg SA, et al. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J Immunol. 2004;173:7622-7629.
15. Zhou J, Dudley ME, Rosenberg SA, et al. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother (1997). 2005;28:53-62.
16. Le Gal FA, Widmer VM, Dutoit V, et al. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol. 2007;127:622-629.
17. Hirsch VM, Lifson JD. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol. 2000;49:437-477.
18. Flynn JL, Capuano SV, Croix D, et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb). 2003;83:116-118.
19. Geretti AM. Simian immunodeficiency virus as a model of human HIV disease. Rev Med Virol. 1999;9:57-67.
20. Lockridge KM, Sequar G, Zhou SS, et al. Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol. 1999;73:9576-9583.
21. Dubois A, Berg DE, Incecik ET, et al. Transient and persistent experimental infection of nonhuman primates with Helicobacter pylori: implications for human disease. Infect Immun. 1996;64:2885-2891.
22. Clay CC, Rodrigues DS, Brignolo LL, et al. Chemokine networks and in vivo T-lymphocyte trafficking in nonhuman primates. J Immunol Methods. 2004;293:23-42.
23. Clay CC, Rodrigues DS, Harvey DJ, et al. Distinct chemokine triggers and in vivo migratory paths of fluorescein dye-labeled T Lymphocytes in acutely simian immunodeficiency virus SIVmac251-infected and uninfected macaques. J Virol. 2005;79:13759-13768.
24. Hamann A, Klugewitz K, Austrup F, et al. Activation induces rapid and profound alterations in the trafficking of T cells. Eur J Immunol. 2000;30:3207-3218.
25. Iparraguirre A, Weninger W. Visualizing T cell migration in vivo. Int Arch Allergy Immunol. 2003;132:277-293.
26. Westermann J, Sollner S, Ehlers EM, et al. Analyzing the migration of labeled T cells in vivo: an essential approach with challenging features. Lab Invest. 2003;83:459-469.
27. Weston SA, Parish CR. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods. 1990;133:87-97.
28. Horan PK, Melnicoff MJ, Jensen BD, et al. Fluorescent cell labeling for in vivo and in vitro cell tracking. Methods Cell Biol. 1990;33:469-490.
29. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994;171:131-137.
30. Fazekas de St Groth B, Smith AL, Koh WP, et al. Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: a marriage made in heaven. Immunol Cell Biol. 1999;77:530-538.
31. Mintern J, Li M, Davey GM, et al. The use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo. Immunol Cell Biol. 1999;77:539-543.
32. Schneider T, Ullrich R, Bergs C, et al. Abnormalities in subset distribution, activation, and differentiation of T cells isolated from large intestine biopsies in HIV infection. The Berlin Diarrhoea/Wasting Syndrome Study Group. Clin Exp Immunol. 1994;95:430-435.
33. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J Immunol. 2000;165:6047-6055.
34. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
35. Surman DR, Dudley ME, Overwijk WW, et al. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000;164:562-565.
36. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277-286.
37. Goedegebuure PS, Douville LM, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol. 1995;13:1939-1949.
38. Curti BD, Ochoa AC, Powers GC, et al. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clin Oncol. 1998;16:2752-2760.
39. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (1997). 2003;26:332-342.
40. Topalian SL, Muul LM, Solomon D, et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987;102:127-141.
41. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20:143-148.
42. Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003;9:619-624.
43. Yee C, Gilbert MJ, Riddell SR, et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 1996;157:4079-4086.
44. Garlie NK, LeFever AV, Siebenlist RE, et al. T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer. J Immunother (1997). 1999;22:336-345.
45. Lum LG, LeFever AV, Treisman JS, et al. Immune Modulation in cancer patients after adoptive transfer of Anti-CD3/Anti-CD28-costimulated T cells-phase i clinical trial. J Immunother. 2001;24:408-419.
46. Testi R, Phillips JH, Lanier LL. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular [Ca++] and stimulation of protein kinase C. J Immunol. 1989;142:1854-1860.
47. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97-108.
48. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-8063.
49. Cui C, Stevens VC, Schwendeman SP. Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine. 2007;25:500-509.
50. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev Biol Stand. 1998;92:63-78.
51. Fonteneau JF, Larsson M, Somersan S, et al. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. J Immunol Methods. 2001;258:111-126.